Jade Biosciences, Inc. Stock Split Ratio
Jade Biosciences, Inc. (JBIO) had Stock Split Ratio of 32.20% as of 2022-06-22, per its 10-Q filed 2022-11-14.
Discontinued › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2023-05-15
- 2022-06-22: Stockholders' Equity Note, Stock Split, Conversion Ratio 32.20%.
- 2021-06-22: Stockholders' Equity Note, Stock Split, Conversion Ratio 32.20%; Stockholders' Equity Note, Stock Split, Conversion Ratio as first filed 32.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio as first filed |
|---|---|---|
| 2022-06-22 | 32.20% 10-Q · filed 2022-11-14 | |
| 2021-06-22 | 32.20% 10-Q · filed 2023-05-15 | 32.00% 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |